C91 D47 C82 C83 C85 C90
Conditions
Interventions
Group 1: During the primary inpatient phase following CAR-T cell therapy, neurological monitoring is conducted using the Immune Effector Cell Encephalopathy (ICE) score, assessed both through the esta
Sponsors
Medizinische Fakultät der TU Dresden, Medizinische Klinik I
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Indication for CAR T-cell therapy - Signed consent form for participation in oncological research at University Hospital Dresden
Exclusion criteria
Exclusion criteria: - Inability to consent - Language barrier - Reduced cognitive or physical ability to use the app or complete smell tests
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of successfully completed and documented ICE score assessments using digital monitoring compared to the paper-based method within 10 days after CAR T-cell infusion during the inpatient stay | — |
Secondary
| Measure | Time frame |
|---|---|
| - Time required per assessment as a sample measurement: comparison of the time needed between the digital and paper-based methods - User satisfaction: evaluation of satisfaction among users (e.g., nursing staff and physicians) using standardized questionnaires - Accuracy and consistency: concordance of results between the digital and paper-based methods - Proportion of successfully completed standardized smell tests relative to the planned number of tests - Correlation between smell test results and the occurrence of ICANS | — |
Countries
Germany
Contacts
Public ContactMartin Schneider
Medizinische Fakultät der TU Dresden, Medizinische Klinik I
Outcome results
None listed